Navigation Links
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
Date:9/23/2009

n a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is built upon Abbott's market-leading bare metal stent, the MULTI-LINK VISION(R) Coronary Stent System. The VISION platform is designed to facilitate ease of delivery, making it easier for physicians to maneuver the stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

Abbott's market-leading XIENCE V drug eluting stent is commercially available in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(R) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
9. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
(Date:10/17/2014)... 17, 2014 Research and Markets ... and Development Prospect of China Dialysis Market, 2014-2018" ... Based on the 2013 version, this update Report ... dialysis industry and the relevant effect in recent ... industry segmentations. Moreover, it analyzes Chinese private-owned hemodialysis ...
(Date:10/17/2014)... Oct. 17, 2014 The following is ... Policy: The Green Park Collaborative (GPC) ... and private payers, medical device and pharmaceutical companies, ... experts January 12, 2015 at its first ever ... weight loss treatments.  Participants will discuss study designs ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... 23, 2011 Varian Medical Systems (NYSE: VAR ... at the annual meeting of the American Society for Radiation ... financial community are invited to join senior management for a ... will host a meeting with management, beginning with breakfast at ...
... NEW YORK, Aug. 23, 2011 ITelagen, Inc., a leading ... that the company was named to the prestigious 2011 Inc. ... growing companies in America. This was the second ... 5000 and was placed on the list at position #2093, ...
Cached Medicine Technology:Varian Medical Systems Schedules Investor Meeting at ASTRO in Miami Beach, FL 2ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies 2
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... October 20, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Sit and Slim II ... not to purchase or use Sit and Slim II because ... II is promoted as weight loss product on various websites ... the market in 2010 for safety reasons, can significantly increase ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium organic ... to celebrate this month. October marks Italian Heritage Month – ... of Americans of Italian heritage and Italians in America. October ... its favorite Italian cocktails and encourages everyone to enjoy its ... it is only in a glass. , Punzoné continues ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... Anticipating the needs of,the future, Geneva College will ... in the nation., Drawing on Geneva,s long-standing ... the program offers students a M.S. degree in,Cardiovascular ... of obtaining a B.S. (in four years) or ...
... 28, 2008 Oxytocin was originally studied as the ... for breast-feeding. However, there is increasing evidence that ... bonding and maternal behaviors. A new study scheduled ... Biological Psychiatry now shows that one way oxytocin ...
... of Liverpool has found that hypnosis can slow down ... for those living with the condition. , Forensic psychologist, ... people living with dementia and compared the treatment to ... hypnosis compared to a type of group therapy in ...
... MASummer on Cape Cod is synonymous with a surge ... the MBL (Marine Biological Laboratory). For more than a ... from around the world to immerse themselves in biological ... organisms available for study and the wealth of experts ...
... more resistance, study found , , MONDAY, July 28 (HealthDay ... even act out when nurses or other caregivers use ... , Researchers who taped the interactions of nursing home ... residents often became more agitated and resistant to care ...
... LLC launches new website offering convenient http://www.terrimilen.com [Online Counseling ... the comfort of their own home or office. , ... ... to provide clients with an alternative to traditional therapy which requires ...
Cached Medicine News:Health News:Geneva Offers First Cardiovascular Technology Graduate Program in the Nation 2Health News:A hormone that enhances one's memory of happy faces 2Health News:LabBits: A media tip sheet from the MBL in Woods Hole 2Health News:LabBits: A media tip sheet from the MBL in Woods Hole 3Health News:LabBits: A media tip sheet from the MBL in Woods Hole 4Health News:Alzheimer's Patients React Poorly to 'Elderspeak' 2Health News:Alzheimer's Patients React Poorly to 'Elderspeak' 3Health News:Online Counseling and Life Coaching Practice Launches New Website 2
... of Surgical Microscope Accessories includes digital camera ... cables, and fiberoptic retrofits. TTI Medical's patented ... 5,264,928) is the only adaptor that will ... the same adaptor body. It is fully ...
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... WAVEFRONT ANALYZER provides a complete ... the entire eye. Real-time measurements ... aberrations in many different forms ... higher order aberrations, Zernike polynomials, ...
Medicine Products: